Anondita Medicare Ltd Q2FY26 – The Condom King’s ₹54 Crore Seduction with 126% Profit Eruption
1. At a Glance
Once upon a latex time, India got a new FMCG contender that doesn’t sell soaps, fairness creams, or noodles — it sells confidence. Anondita Medicare Ltd, the maker of the now-famous “COBRA” condoms, has stormed into the SME markets like a well-aimed shot. With a market cap of ₹1,125 crore, a stock price of ₹622, and an almost risqué P/E of 49x, this baby is growing faster than Tinder downloads on Valentine’s week.
In Q2FY26, Anondita clocked ₹54 crore in sales (up 72.2% YoY) and a PAT of ₹12.9 crore (up 126% YoY). That’s right — profits doubled while half the market was still giggling at the IPO prospectus. Its Operating Profit Margin sits at a juicy 33.4%, proving that this company knows how to perform… financially, of course.
The ₹65.5 crore IPO from September 2025 gave them enough cash to add capacity, buy machinery, and polish the “COBRA” brand into a market slayer. With promoters holding 61.8%, and institutions like SageOne and Cognizant Capital watching closely, this isn’t a joke stock — it’s a serious play in India’s most private public sector: safe pleasure.
2. Introduction – The Rise of the Latex Lakhpatis
Let’s be honest — you don’t expect the next “FMCG growth story” to come wrapped in foil. But Anondita Medicare is here to change that. Founded in March 2024, the company has already managed what many legacy FMCG players take decades to achieve: brand recall. “COBRA” isn’t just a name; it’s a punchline, a brand, and apparently a very profitable business.
The post-pandemic years made India hygiene-obsessed. While others were peddling sanitizers, Anondita was busy preparing for the real public health demand — condoms that are safe, fun, and yes, flavored. Its flagship product range spans from classic latex to fruity adventures, and the company even started producing female condoms, a rarity in India’s market.
Their biggest customer isn’t the guy next door; it’s the Government of India itself. Through CMSS and various State AIDS Control Societies, Anondita’s products reach lakhs of citizens under public health programs. When the government buys your product in bulk and pays on time, that’s not a business — that’s a dream with margins.
With a strong domestic base across Delhi, UP, and beyond, plus UN qualification pending for exports, Anondita’s ambitions go way beyond India’s borders. Africa and Southeast Asia — markets they once supplied to — could soon see COBRA rise again.
3. Business Model – WTF Do They Even Do?
Anondita’s business model is simple, but its execution is precise. They manufacture condoms — male and female — in their 11,000 sq. ft. Noida plant, with an installed capacity of 56.2 crore pieces per annum. The factory runs at about 39% utilisation, which means a ton of unused capacity waiting to explode (pun intended).
Their flagship “COBRA” brand accounts for almost all their sales. The company’s in-house printing and packaging setup ensures better control, faster delivery, and lower costs. Every product undergoes 100% electronic testing, giving it a quality seal stronger than most listed auditor reports.
The customer mix is deliciously stable:
Government tenders (CMSS, State AIDS Control) – The steady, high-volume contracts.
Distributors (Calcutta Cosmetics) – Keeps the commercial flow alive.
Subsidiary sales (Anondita Healthcare & Rubber Products India Ltd) – An internal loop of efficiency and control.
With almost 99.9% of revenue coming from condoms, they’ve officially retired from pandemic-era mask and glove sales. Instead, they’re expanding into female condoms, a niche where margins are strong and competition is laughably low. The company’s R&D and patent application for female condom manufacturing shows it’s thinking long-term — and globally.
